Background: Orbital morphological changes are often present in patients with Graves' disease (GD) already at diagnosis, and cyclooxygenase type 2 (COX-2) is overexpressed in active Graves' ophthalmopathy (GO). Objective: To investigate if adjuvant treatment of GD with the COX inhibitor and peroxisome proliferator-activated receptor-γ (PPAR-γ) antagonist diclofenac decreases the development of ophthalmopathy and if laboratory parameters are affected. Methods: This is a multicenter trial where 61 subjects were randomized to methimazole (block and replace with L-thyroxine) either with or without diclofenac 50 mg 1 × 2 for 12 months. The primary end point development of GO after 24 months was evaluated. Smoking habits were registered and the thyroid parameters TSH, free T4, free T3, TSH receptor antibodies (TRAb) and anti-TPO were followed. Safety parameters (kidney, liver and blood) and adverse events were regularly registered. Results: GO developed in 11% (n = 3) of the patients treated with diclofenac and in 21% (n = 6) of the controls (p = 0.273). The adverse event profile was acceptable without any severe events related to diclofenac. Both TRAb and anti-TPO concentrations decreased during treatment with methimazole, but the anti-TPO concentrations were lower in patients treated with diclofenac after 15 months (p = 0.031). The TRAb concentrations were not significantly changed between groups. Smokers had higher concentrations of TRAb than nonsmokers both at diagnosis of GD (p = 0.048) and after 15 months (p = 0.042). Conclusions: Treatment with diclofenac had no significant influence on development of GO. Diclofenac reduces anti-TPO concentrations and seems to be safe to use in GD patients.

Keywords:
Smoking, Diclofenac, Anti-TPO, TSH receptor antibodies
1.
Burch HB, Wartofsky L: Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-793.
2.
Hägg E, Asplund K: Is endocrine ophthalmopathy related to smoking? Br Med J 1987;295:634-635.
3.
Wiersinga WM: Smoking and thyroid. Clin Endocrinol 2013;79:145-151.
4.
Tallstedt L, Lundell G, Törring O, Wallin G, Ljunggren J-G, Blomgren H, Taube A: Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-1738.
5.
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera: A relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-78.
6.
Träisk F, Abraham-Nordling M, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Tallstedt L, Taube A, Törring O, Wallin G, Åsman P, Lundell G: Thyroid associated ophthalmopathy: occurrence after treatment for Graves' hyperthyroidism with iodine-131 or anti-thyroid drugs. J Clin Endocrinol Metab 2009;94:3700-3707.
7.
Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M: PPARgamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003;88:55-59.
8.
Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B: Treatment with thiazolidinedione increases eye protrusion in a subgroub of patients with type 2 diabetes. Clin Endocrinol 2006;65:35-39.
9.
Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima M, Ikeda Y: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22:908-912.
10.
Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS: Stimulation of adipogenesis, PPARgamma and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 2002;87:2352-2358.
11.
Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN: Diclofenac antagonizes PPARgamma signaling. Mol Pharmacol 2002;61:7-12.
12.
Vondrichova T, Capretz A, Parikh H, Frenander C, Åsman P, Åberg M, Groop L, Hallengren B, Lantz M: COX-2 and SCD, markers of adipogenesis, are related to disease activity in Graves' ophthalmopathy. Thyroid 2007;17:511-517.
13.
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-deoxy-prostataglandin J2 is a ligand for the adipocyte determination factor PPARgamma. Cell 1995;83:803-812.
14.
Lantz M, Vondrichova T, Parikh H, Frenander C, Ridderstråle M, Åsman P, Åberg M, Groop L, Hallengren B: Overexpression of immediate early genes in active Graves' ophthalmopathy. J Clin Endocrinol Metab 2005;90:4784-4791.
15.
Amemia T: Long-term indomethacin treatment of ophthalmopathies after Basedow disease in general practice (in German). Klin Monatsbl Augenheilkd 1982;181:286-289.
16.
Bloise W, Mimura LY, Moura J, Nicolau W: Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study. Arq Bras Endocrinol Metabol 2011;55:692-695.
17.
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L: Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013;98:1443-1449.
18.
Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P: Treatment of Graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007;156:33-40.
19.
Ryan EP, Pollack SJ, Murant TI, Bernstein SH, Felgar RE, Phipps RP: Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol 2005;174:2619-2626.
20.
Kim JN, Kim HJ, Jeong SH, Kye YC, Son SW: Cigarette smoke-induced early growth response-1 regulates the expression of the cysteine-rich 61 in human skin dermal fibroblasts. Exp Dermatol 2011;20:992-997.
21.
Planck T, Shahida B, Parikh H, Ström K, Åsman P, Brorson H, Hallengren B, Lantz M: Immediate early genes are overexpressed in smokers with Graves' ophthalmopathy compared to non-smokers. Thyroid 2014;24:1524-1532.
22.
Hegedüs L, Bliddal H, Karstrup S, Bech K: Thyroid stimulating immunoglobulins are not influenced by smoking in healthy subjects. Thyroidology 1992;4:91-92.
23.
Nyirenda MJ, Taylor PN, Stoddart M, Beckett GJ, Toft AD: Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers vs nonsmokers with Graves' disease treated with carbimazole. JAMA 2009;301:162-164.
24.
Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Erlandsson Harris H, Ulfgren A-K, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigen modified by citrullination. Arthritis Rheum 2006;54:38-46.
25.
Calissendorff J, Lantz M, Catrina SB: Antibodies to citrullinated protein antigen are not biomarkers for Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2012;77:329.
26.
Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines CK, Ling S, Chinnaiyan AM, Holoshitz J: Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 2006;54:2047-2060.
27.
Planck T, Shahida B, Sjögren M, Groop L, Hallengren B, Lantz M: Association of polymorphisms in CTLA4, BTG2, CYR61, ZFP36 and SCD with Graves' disease and ophthalmopathy. Thyroid 2014;24:1156-1161.
© 2016 European Thyroid Association Published by S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.